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Abstract:  Cathepsin G (CatG) is a chymotrypsin-like protease released upon 
degranulation of neutrophils. In several inflammatory and ischaemic diseases the 
impaired balance between CatG and its physiological inhibitors leads to tissue destruction 
and platelet aggregation. Inhibitors of CatG are suitable for the treatment of inflammatory 
diseases and procoagulant conditions. DNA released upon the death of neutrophils at 
injury sites binds CatG. Moreover, short DNA fragments are more inhibitory than 
genomic DNA. Defibrotide, a single stranded polydeoxyribonucleotide with 
antithrombotic effect is also a potent CatG inhibitor. Given the above experimental 
evidences we employed a selection protocol to assess whether DNA inhibition of CatG 
may be ascribed to specific sequences present in defibrotide DNA. A Selex protocol was 
applied to identify the single-stranded DNA sequences exhibiting the highest affinity for 
CatG, the diversity of a combinatorial pool of oligodeoxyribonucleotides being a good 
representation of the complexity found in defibrotide. Biophysical and biochemical 
studies confirmed that the selected sequences bind tightly to the target enzyme and also 
efficiently inhibit its catalytic activity. Sequence analysis carried out to unveil a motif 
responsible for CatG recognition showed a recurrence of alternating TG repeats in the 
selected CatG binders, adopting an extended conformation that grants maximal 
interaction with the highly charged protein surface. This unprecedented finding is 
validated by our results showing high affinity and inhibition of CatG by specific DNA 
sequences of variable length designed to maximally reduce pairing/folding interactions.  
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1. Introduction 
 
Cathepsin G (CatG) is a serine protease commonly found in the azurophilic granules of 
polymorphonuclear leukocytes and mast cells [1]. Together with elastase and proteinase 3 it belongs to 
the chymotrypsin family and cleaves extracellular matrix proteins such as elastin, collagen, fibronectin 
and laminin causing extensive lung tissue damage [2]. 
As for other peptidases, several biological functions can be exerted by CatG. In blood clotting the 
enzyme is involved in an alternative pathway of leukocytes initiation of coagulation by activating 
coagulation factor X [3] and factor V [4]; it can also cleave and potentially modulate thrombin 
receptor and activate platelets in vitro [5]. CatG can degrade necrotic tissues and is therefore related to 
several pulmonary inflammatory diseases like lung emphysema [6], bronchitis [7] and cystic fibrosis 
[8], as well as a variety of other pathological conditions associated with inflammation [9]. 
The enzymatic activity of Cathepsin G is physiologically regulated by two types of proteinase 
inhibitors: the so called “canonical” inhibitors and the serpins (serine protease inhibitors). The former 
are relatively small proteins (29-190 amino acids) acting as tight-binding reversible inhibitors; among 
them Mucus Proteinase Inhibitor (MPI) [8], eglin c [10] and aprotinin deserve to be mentioned [11]. 
Serpins are larger proteins (400-450 residues) that form an irreversible complex with their target 
protein through the formation of a non-hydrolysable acyl bond between the catalytic site of the 
protease and their reactive site loop. Among serpins, α1-antichymotrypsin is the most relevant 
inhibitor of CatG. These kinds of inhibitors are not suitable for therapeutic use. In fact, they are all non 
selective as they can bind and inhibit other chymotripsins [12]. Besides, their stability and distribution 
in vivo is strongly affected by their peptidic nature. Thus, the research is mainly directed to the 
discovery and development of non-peptidic inhibitors of CatG with higher selectivity.  
Negatively charged macromolecules are effective inhibitors of cathepsin G: this is not surprising, 
since the enzyme is a very basic protein, exhibiting 36 positively charged residues not compensated by 
neighbouring counter charges [13]. CatG is indeed able to form 1:1 complexes with low molecular 
weight heparins [14], as well as with heparin-like dextran derivatives and glycosamminoglycans [15-
17]. However, heparins exhibit undesired side effects due to their low specificity for this target. 
A polyanion macromolecule as DNA was shown to be able to bind and inhibit the enzyme in vitro 
and in vivo [18-20]. In particular, DNA fragments shorter than 0.5 kb of genomic origin like those 
produced by DNAse treatment in patients with cystic fibrosis [21] as well as a 30 bp DNA fragment  
bind CatG very efficiently at physiological conditions [20]. These short DNA fragments with random 
sequences have higher affinity for cathepsin G than for human neutrophil elastase and proteinase 3, 
specificity in accordance with the decreasing cationic character and different localization of arginines 
[21].  Int. J. Mol. Sci. 2008, 9  1010
 
 
Short nucleic acid fragments could hence be considered as specific CatG inhibitors that, differently 
from serpins, act in a reversible way. In fact, defibrotide, a complex mix of single stranded   
polydeoxyribonucleic acid sequences of genomic origin with therapeutic use [22-26] is an effective 
inhibitor of cathepsin G, and its antithrombotic effect has been ascribed to the anti-cathepsin G activity 
[27]. We decided to investigate on the binding specificity of defibrotide to the enzyme, i.e. to 
understand whether the recognition of CatG is mediated by specific sequence patterns in the context of 
genomic DNA. In heparin-like dextran compounds recognition of the enzyme has been examined in 
detail, showing that specific derivatives are responsible for CatG regulation:  ionic interactions guide 
the recognition with the positively charged protein, but the initial electrostatic complex is then 
stabilized by non-ionic binding to CatG [16].  
We therefore asked if, in a similar manner, specific sequences present in defibrotide DNA would 
contribute to stabilize complexation with CatG. To identify these sequences, we applied a Selex 
protocol (Systematic evolution of ligands by exponential enrichment) [28] in order to identify ssDNA 
molecules with high affinity for Cathepsin G starting from a highly diverse random pool of synthetic 
oligodeoxyribonucleotides mimicking the natural defibrotide of genomic origin. Selex allows the 
screening and PCR amplification of the random-sequence pool followed by identification of the best 
binders to the desired target, and it is based on the assumption that some oligonucleotides in the highly 
diverse combinatorial pool may possess desirable features to assure selectivity to the target molecule. 
Although inhibition is not always demanded by the selection protocol, in many instances these ligands 
inhibit the biological functions of the targeted proteins as in pegaptinib, a pegylated aptamers against 
VEGF. It is remarkable that, although oligonucleotides stability in vivo is low, aptamers half life in 
biological fluids can be improved through pre- and post-Selex modifications: pegaptinib is in fact a 
marketed drug [29].  
Indeed, our selection allowed us to characterize several single stranded oligodeoxyribonucleotides 
with optimal sequence and length that tightly bind Cathepsin G. The analysis of the selected CatG 
binders unveiled the presence of imperfect TG repeats as common motifs and allowed us to prove that 
alternating oligopolymers with extended conformations and precise length are preferred CatG binders 
and inhibitors. 
 
2. Results  
 
2.1 Selection of CatG binders from a random DNA pool 
 
Specific Cathepsin G binders were selected from a synthetic oligodeoxyribonucleotide pool 96 
nucleotides long; the randomised 60 central bases has a length and theoretical diversity mimicking the 
molecular diversity of defibrotide (average molecular weight ≅ 21 KDa); the random combinatorial 
region is flanked by two conserved regions of 18 nucleotides needed for PCR amplification and 
cloning steps. 
CatG has a theoretical pI of 11.0, thus in our working conditions (pH 7.5) it shows a positive net 
charge. This property allowed us to incubate CatG and DNA in solution, and perform selection with a 
cation exchanger resin like sulphopropyl (SP) Sepharose. In this system, the non-specific binding of 
DNA molecules to the underivatized Sepharose SP resin is minimal and non-influential: only CatG, Int. J. Mol. Sci. 2008, 9  1011
 
 
free or  DNA bound,  is retained onto the column, while those DNA sequences not efficiently bound to 
the enzyme can be easily washed away prior to elution.  
The incubation between DNA and the protein was performed in the presence of NaCl, KCl and 
MgCl2 (150, 5 and 5 mM respectively). High salt concentration could favour selectivity in binding by 
reducing the expected strong electrostatic interactions between oligonucleotides and protein, as shown 
by Duranton [20]. Additionally, monovalent cations like sodium and potassium may stabilize G 
quartets, which are among the most common folding motifs exhibited by ssDNA aptamers [30]. The 
CatG-bound DNA molecules, labelled at their 5’ end with 
32P, were efficiently removed from the 
column using a higher ionic strength buffer (EB buffer, 0.8 M NaCl), amplified by PCR and then 
reduced to single stranded molecules to be used for the reiteration of Selex cycles. A summary of the 
selection protocol and the yields obtained are reported in Figure 1. 
 
Figure 1. Flowchart of the selection of binders for Cathepsin G from a single stranded 
DNA combinatorial pool. Each selection cycle shown in the figure was reiterated until 
enrichment of the initial pool in CatG binders was obtained (final yield 42%). Yields at 
each cycle are shown in the inset. Precolums were applied between cycles 6 and 7 and 8 
and 9 in order to avoid non-specific binding to the resin. Relative DNA/CatG 
concentrations and washing volumes were changed through the selection to modulate 
stringencies (see text). 
 
The first four cycles of selection were conducted with relatively low immobilized protein (4-12 
ng/ul). Not surprisingly, at cycle 4 a significant increase in the yield of DNA binders was observed, 
reflecting the favourable electrostatic binding. To reduce yield the concentration of immobilized 
protein was reduced and washings were increased until the final cycles, where higher protein 
concentration were allowed. Two precolumn cycles were used in order to avoid the minimal unspecific 
binding of the DNA to the matrix of the resin.  Int. J. Mol. Sci. 2008, 9  1012
 
 
The Selex was terminated after the ninth cycles: at this point the enrichment of the pool, 
considering the final yield of 42 %, was considered satisfactory. To confirm this, three supplementary 
rounds of selection (not shown) did not produce further increase in pool affinity to CatG.  
The selected oligodeoxyribonucleotide molecules were finally PCR amplified, cloned in E.coli and 
sequenced through Sanger method. 19 different sequences from positive clones are listed in Table 1.  
 
Table 1. Sequences of the selected DNA-CatG binders 
 
Clone   DNA sequence 
CG1  GGGTGGCCCCCTAGTCGCGCACTGGAAGCGGTAGTGTCGTGAGATTCGTATCTGGGGTAT 
CG3  CAACGAGTCAGGGCGTGATTGGTGAAGATGTGTGGTTTGGCCAGAAAGGGCGATGGTGGA 
CG11  AGAGCTGAGACGGACATGCTGCCCATGGAGACTGTTCGAGAGGGTGAGCGGGAGTGGG 
CG16  ACCCCTAGGTCAGCACGTAGTGTAGGGCGATGTGTTCATGGCGGGAATGTGAGTTGTGGG 
CG20  GGGCGGCTCGCGTTGTGGAACATTCGTGGTGCCAATGCGTACCAGGGATTGCCTCCTGT 
CG25  GGGCGATTGGCGAATGCAAGGGTAAGGTTGGGCGATTGATGTGCACGTAGCGCAGAGCAT 
CG28  XXGGAACGTGGTAGGTGTGTCTGCTGTGTGTGGCTCGGGCAGGTTGTCAGGGTGTTT 
CG32  GGGCATAGGGCGTCGTAGCCTGAAGGTGTGATTCGTGCGTTAGATGGGGGGCAGTCTGC 
CG43  CAACGTGTGATATGTGGGTATACGCTTGGGTGTTACGCTGAGCACAGAGGGTATTCGTGT 
CG45  GGCGGGCGGTATGGGCTGCAGGATATGCAGGGGCGCAGAGGACAGTCTGGCCATGTACTA 
CG49  GGCCTGGGTGATGTACTATGTATGCGTCGTGGTGGCTGGTAAAGGGGGTCTGCTATGGGT 
CG51  CAACGTGTGATATGTGGGTATACGCTTGGGTGTTACGCTGAGCACAGAGGGTATTCGTGT 
CG2  CCACGGACGCTGTGAGCGGCCAACGGATGGGAATCACGATCTGGCCCGAACCACATACCG 
CG31  TCACACTAGGGCACTTGCTAAGTAGCTATGTAACTCGATCATACTTATTAGGCTTG 
CG23  AATCGATGGACACTTCAACGCAACTTGACATGGCGGTACGTGGACTCTTGTGGCGACAGTT
CG34  AACCCGTGTGATAAGGATATGGTGACTTCGTGGCACAGCGTCGACGGACTGCCCATTCCA 
CG40  GGCAGGGACGTTCCCAGGAATGCGGCACAGGCAGACAGCTCCCGACGAGTACCAGGGTG 
CG48  AGXGGGCAGCAGCACACCACACATGTACGTGGGGGATTGCATTGTGTACTTAGACGGTAT 
CG39  CGGTGGAGAGGTCGCAATGACACGGTTGACGATAGGCCCCTTGCTAACATCGGTTGGTG  
 
2.2 Identification of structural motifs in DNA - CatG binding 
 
The DNA sequences obtained by the selection and shown in Table 1 were analyzed with FastA 
ALIGN and Clustal X [31-33] to evidence if common motifs were present among the 20 different 
identified sequences of CatG binders. Alignment of sequences however did not evidence a common 
consensus. Hence, we analyzed the DNA with Mfold [34], a program able to evaluate the formation of 
stable folding raising from inter- or intra-molecular Watson Crick base pairing. Mfold analysis of 
CatG DNA binders yielded very low energy values associated to the predicted folded conformations of 
DNA molecules, with average free energy values around -3 kcal/mol. These findings support the 
observation that no common sequence can be found in the selected CatG binders, pointing out the lack 
of a precise three-dimensional motif related to the recognition of the protein.  Int. J. Mol. Sci. 2008, 9  1013
 
 
None of the selected CatG binders tend to self-dimerize into double stranded conformations: a close 
examination of the sequences as well as their predicted folding evidenced long stretches of unpaired 
sequences characterized by short alternating dTdG or dGdT. Sequences have an average content of Ts 
and Gs around 65%. Among these, clones CG1, CG3, CG11, CG16, CG20, CG28, CG45, CG48, 
CG49 and CG51 were those enriched in TG elements.  
Indeed, it is well known that eukaryotic genomes contain many short tandem repeats of very simple 
motifs (usually dinucleotides) [35], and the human genome has approximately 10
5 copies of stretches 
of dT-dG alternating sequence [36].  TG elements are randomly dispersed in the genome but are stable 
components present throughout the evolution of eukaryotic genomes, with a molecular size between 
20 and 60 dinucleotide repeats [37]. Since defibrotide is a single strand polydeoxyribonucleotide 
resulting from digestion of mammalian genomic DNA, it is likely that TG elements are highly 
represented motifs, possibly responsible for Cathepsin G recognition and inhibition. If this is the case, 
the selected clone sequences had identified alternating non-self complementary 
oligodeoxyribonucleotides of defined length as a class of CatG binders.  
To prove this hypothesis we compared the affinities of several linear alternating 
oligodeoxyribonucleotides employing the protocol used for the Selex. The sequence CG51 has a 
predicted folding at 150 mM NaCl and 5 mM Mg
2+ of -2.52 kcal/mol, well in the range of those 
exhibited by all other selected CatG binders, and it has therefore been chosen as representative of 
DNA-CatG binders. A quantitative analysis of the oligo-protein binding process allowed to compare 
the dissociation constant of CG51 with that of the linear alternating polymer (dT-dG)30. As controls, 
we measured the affinities of the alternating non self-complementary oligodeoxyribonucleotide (dA-
dC)30 and of the complementary sequence of CG51, cCG51. Defibrotide, whose molecular weight is 
consistent with those of other oligos, represents our random sequence control.  Additional controls are 
two aptamers identified in Selex protocols toward different targets. One is pE35, a 60 bases aptamer 
selected in our lab [38] with good affinity and specificity toward L-Tyr [39]. The second is a short (5 
KDa) and highly structured oligo, THR, a DNA aptamer with G-quartets arrangement selected against 
the serine protease thrombin [40]. 
As reported in Figure 2A, we found that the selected aptamer CG51, its complementary strand 
cCG51, as well as (dT-dG)30 and (dA-dC)30, showed comparable binding affinity values, proving our 
hypothesis that CatG Selex had helped identify linear alternating oligodeoxyribonucleotides rich in 
dinucleotide repeats as enzyme binding motifs. The folded G-quartet organized THR aptamer does not 
show an appreciable affinity for the protein, as well as pE35, an aptamer for a different target with 
comparable length to CG51. Defibrotide showed the lowest affinity for CatG among all the tested 
oligonucleotides, consistently with its sequence complexity.  
Since TG repeats found in genome have a molecular size ranging from 20 to 60, we explored the 
effect of length of TG repeats in CatG recognition evaluating the dissociation constants of a number of 
(dT-dG)n derivatives (where n is the degree of polymerization) (Figure 2B).  
As summarized in Figure 2B, irrespective of the nucleotide sequence, we found a bell shaped 
dependence of Kd as a function of aptamer length, with molecules 60-80 nucleotides long being the 
best binders, consistently with the size of the oligonucleotides random pool employed in the Selex 
protocol as well as of defibrotide.  Int. J. Mol. Sci. 2008, 9  1014
 
 
The CatG-DNA binding process was additionally monitored by SPR, a different technique 
employing immobilized CatG onto a chip surface. Several linear (dT-dG)n and (dA-dC)n 
oligodeoxyribonucleotides of different length were tested and their dissociation from enzyme 
compared. A first data set was generated using a variable molar concentration of each oligonucleotide. 
Results are summarized in Figure 3, where the Log concentration-effect curves using the test 
sequences, referring to the concentration range over which a linear regression was obtained, are 
reported.  
 
Figure 2.  A) CatG binding properties of tested oligonucleotides. The dissociation 
constants (Kd) of selected CatG binders, the TG oligonucleotides (dT-dG)30 and 
appropriate controls were evaluated by chromatography and reported as a function of DNA 
sequence. B) CatG binding properties of TG oligonucleotides. The dissociation constants 
(Kd) of different TG oligonucleotides were analyzed as a function of DNA chain length.  
 
 
 
Figure 3. CatG binding properties of TG and AC oligonucleotide series.  Dependence of 
CatG binding upon oligonucleotide concentration for (dT-dG)n and (dA-dC)n  sequences 
determined by SPR data.  
 
 
 
Under these conditions, (dT-dG)50 appears to be a somewhat more potent binder than (dT-dG)40 , 
although the latter yields the largest resonance signal. CatG recognition is substantially poorer with 20-Int. J. Mol. Sci. 2008, 9  1015
 
 
30mers. It should be noted that increasing the chain length over 60 bases brings forth an increase in 
binding affinity but this increment is less steep than that in the range 30-60. This rank order is shared 
by all the sequences tested although we found a reduced binding for (dA-dC)n derivatives in 
comparison to (dT-dG)n ones at the high molecular weight.  
 
2.3 Inhibition of CatG catalytic activity 
 
The enzymatic activity of CatG was determined in the presence of increasing concentration of the 
selected CatG binders and of the alternating (dT-dG) repeats. The catalytic inhibition properties were 
evaluated by monitoring the reduction in the hydrolysis rate of an appropriate chromogenic peptide 
substrate. According to literature data, an hyperbolic non-competitive tight binding mechanism for the 
DNA-CatG interaction has been confirmed [20]. In fact DNA sequences inhibit enzyme activity at 
concentrations comparable to the protein (nM) concentration. The inhibitory effects obtained with 
DNA chains of different sequences but comparable length appear to be poorly affected by the 
sequence (Figure 4A). However, a role of the chain length clearly emerges using the TG repeats series, 
the inhibitory activity of which varies substantially with the number of residues (Figure 4B).  
 
Figure 4.  CatG inhibition properties of selected oligodeoxyribonucleotides. The relative 
inhibition data are reported as a function of DNA sequence (Panel A) or (dT-dG) chain 
length (Panel B). 
 
 
 
 
In particular, while chains 20-60 bases long share comparable activity, longer chains exhibit a 
progressive increment in their inhibitory efficiency.  Additionally, a residual enzymatic activity of 
about 25% is retained by the protein-DNA complex when the oligonucleotide chain length does not 
exceed 40 bases, whereas it is almost doubled for oligos 60 or more bases long. This effect can be 
explained by the fact that the shorter oligonucleotides more likely interact with CatG on a 1:1 basis 
[16], whereas in the presence of longer sequences more than one protein molecule can bind 
simultaneously to each oligonucleotide chain. The inhibition effect of oligos on CatG was not affected 
by the presence of a charged protein like albumin, indicating that inhibition is selective (not shown). 
 Int. J. Mol. Sci. 2008, 9  1016
 
 
3. Discussion 
 
The in vitro selection of CatG binders was successfully accomplished and allowed to identify the 
oligodeoxyribonucleotide sequences that bind tighter to the enzyme within a highly complex 
population of DNA sequences mimicking defibrotide, a nucleic acid of genomic origin. We validated 
the remarkable affinity of CG51 for CatG with a Kd in the micromolar range, showing that the 
selection had effectively led to a pool of efficient binders. 
Remarkably, the sequence analysis of the selected binders did not disclose a defined consensus 
motif, and well established algorithms used to evaluate folding of nucleic acids indicated that the 
identified aptamers do not tend to fold into stable and defined three-dimensional conformations. Due 
to the highly charged character of CatG, a reasonable hypothesis for the lack of a defined common 
consensus sequence is that the recognition process was essentially based upon the optimization of 
ionic interactions with DNA. Thus, through the selection protocol, we likely picked out molecules that, 
to better fit onto the accessible protein surface without limiting constraints, do not tend to fold into 
stable structures. Were this hypothesis true, high flexibility and optimal sequence length would 
represent the main factors responsible for the tight binding of some oligonucleotides to the positively 
charged protein. 
Interestingly, CatG binders sequences were enriched in imperfect TG repeats. The analysis of 
binding and catalytic inhibition by alternating TG oligomers confirmed that these motifs may be 
considered excellent CatG binders and inhibitors. To confirm the hypothesis of a peculiar selection 
mechanism based on specific repeat motifs, the affinity of selected CatG binders was compared to that 
exhibited by alternating synthetic oligonucleotides. The dissociation constants for the oligos (dA-
dC)30, (dT-dG)30 and for CG51-complementary sequence (cCG51) were all comparable and close to 
the values found for the oligos identified by Selex. Since all of the above compounds share a poor 
tendency to fold, the selection was indeed driven by the ability of the DNA molecule to stick onto the 
protein surface in an extended and flexible linear form. In the case of CatG, the sequence context plays 
a role exactly opposite to that generally played in producing selection of well defined and structured 
aptamers.  
Notably, the sequences derived from the selection process mimics the abundance of TG repeats in 
genomic DNA and defibrotide, well known CatG inhibitors [21, 27]. TG rich sequences were found 
more frequently than AC steps in the selected aptamers. To account for this, it is reported that dG and 
dT nucleotides have faster coupling times during the random pool synthesis [41], therefore, sequences 
abundant in dA-dC are possibly under-represented in the starting pool. 
The above considerations help explain the poorer CatG-binding properties of defibrotide. In fact, 
although this compound consists of a random mixture of ssDNA molecules of natural origin, they 
however largely undergo intra- as well as intermolecular folding (pairing) equilibria [25], thus 
producing an effective competition  with the process of CatG binding. 
A further indication for the requirement of an unfolded structure comes from the data regarding 
pE35, an aptamer of comparable length of GC51 but with a defined structure [38], that interacts poorly 
with CatG. A shorter but folded aptamer (THR) with high affinity for the serine protease thrombin was 
also evaluated for binding, exhibiting a poor affinity as well. Int. J. Mol. Sci. 2008, 9  1017
 
 
The need for proper DNA length to optimize the binding process has also been evidenced. 
Chromatography data proved that both linearity and length are essential for binding: molecules which 
are 60-80 nucleotides long are tight binders of CatG, while shorter or longer sequences showed poorer 
affinity. These data are in apparent contrast with SPR results, that evidenced a higher affinity for 
longer oligos in the series TG and AC. Using this technique the affinity appears to be almost linearly 
dependent upon the length of the tested oligos. To explain this we should consider that in SPR 
experiments one DNA chain can bind only one protein molecule since the enzyme is covalently 
attached onto the chip surface at low density. On the contrary, the Selex protocols, as well as the 
catalytic inhibition experiments, are based on incubations of protein and DNA in solution with the 
possible formation of different types of complex. Such behaviour has been previously reported for 
complex formation between CatG and glycosamminoglycans [16], negatively charged polyelectrolytes 
exhibiting an extended conformation similar to that shown by DNA-CatG binders. 
Finally, the binding of tested oligonucleotide sequences to CatG induces a modulation in the 
catalytic properties of the enzyme, since CG51 and alternating oligos of the same size are efficient 
binders and inhibitors. Alternating oligopolymers of different length are also good inhibitors of CatG: 
indeed, the enzymatic properties of the protein are strictly dependent on the accessibility and 
conformation of its active site, and different binding mode(s) are likely to affect the catalytic response 
of the complex to different extents.  
In conclusion, our selection allowed to identify the sequences of DNA binders of CatG from a 
combinatorial pool of oligodeoxyribonucleotides mimicking the molecular diversity of defibrotide, a 
known enzyme inhibitors of natural origin. More than one order of magnitude in affinity was gained 
relative to the natural product; it is foreseeable that subjecting CatG aptamers to a further Selex 
protocol may improve the affinity to submicromolar levels. The analysis of the selected binders 
unveiled a new paradigm for the recognition of a specific target by DNA sequences which, instead of 
being based upon a precise nucleic acid folding, rests on an extended, flexible binder conformation for 
maximal interaction with the target protein surface.   
 
4. Experimental Section  
 
4.1 Materials  
 
Cathepsin G was purchased from Europa Bioproducts and dissolved before use in 50 mM sodium 
acetate (pH 5.5) and 150 mM NaCl.  Defibrotide, a product derived from porcine double stranded 
DNA that is treated to produce a family of ssDNA molecules, was produced by Gentium SpA. All 
oligodeoxyribonucleotides were obtained from Eurogentec Bel SA (Belgium) and purified by PAGE 
before use. 
The single stranded DNA (ssDNA) random pool used in the selection against cathepsin G is a 96-
mer with a random region of 60 nucleotides flanked by two constant regions for the primers annealing. 
The estimated complexity of the pool was of 10
16 molecules. Its sequence is: 5’-CGT ACG GAA TTC 
GCT AGC (N)60 GGA TCC GAG CTC CAC GTG-3’, with the underlined region referring to the 
EcoRI restriction site. The sequences of the PCR primers are respectively 5’-CGT ACG GAA TTC Int. J. Mol. Sci. 2008, 9  1018
 
 
GCT AGC-3’ (UP primer) and 5’-CAC GTC GAG CTC GGA TCC-3’( DOWN primer). The latter 
primer has a biotin at its 5’ end. 
Sequences of CatG binders and other oligos used as controls are: 
CAACGTGTGATATGTGGGTATACGCTTGGGTGTTACGCTGAGCACAGAGGGTATTCGTGT 
(CG51),  
ACACGAATACCCTCTGTGCTCAGCGTAACACCCAAGCGTATACCCACATATCACACGTTG 
(cCG51),  
AATTCGCTAGCTGGAGCTTGGATTGATGTGGTGTGTGAGTGCGGTGCCCGGATCC (PE35), 
GGTTGGTGTGGTTGG’ (THR).   
The sequences of the primers used for sequencing are ACG CCA AGC TTG CAT (ELEA57)  
and GGGTTTTCCCAGTCACGA (ELES357).  
 
4.2 Selection of DNA-CatG binders 
 
For the first Selex cycle 20 nmoles of the ssDNA random pool were large scale amplified by PCR 
in a mix (12.5 mL) containing amplification buffer 10x (1.25 mL), dNTPs (1.25 mM each, 2 mL), Taq 
polymerase (100 units, Pharmacia Amersham Biotech) and 25 nmoles of both UP primer and DOWN 
primer. Eight PCR cycles were performed in water baths with this temperature scheme: 4 minutes 94 
°C, 7 minutes 50 °C and 7 minutes 72 °C. The pool was then precipitated in ethanol/acetate, 
resuspended in TE (300 μL) and purified through a G-50 column.  
To generate ssDNA after each PCR we used an alkaline denaturation protocol. Briefly the 
biotinylated DNA, resuspended in SBB buffer (Streptavidin Binding Buffer: NaCl 50 mM, Tris/HCl 
100 mM, EDTA 10 mM) was loaded in a chromatography column filled with streptavidin Sepharose 
resin (Pierce). After 30 minutes incubation, the unbound dsDNA was washed away with SBB buffer 
while the non-biotinylated strand was collected by washing the column with NaOH 0.15 N. After 
precipitation the ssDNA concentration was measured by UV spectroscopy and used for the Selex 
cycles. 
The random pool obtained after large scale PCR amplification and alkaline elution from the 
streptavidin resin was radioactive labelled at 5’ end with [γ-
32P]ATP (NEN Life Science) and T4 
polynucleotide kinase (Amersham). The labelled ssDNA was then denatured at high temperature, 
renatured and incubated with Cathepsin G in Incubation Buffer (IB buffer: 30 mM Tris HCl pH7.5, 
150 mM NaCl, 5 mM KCl and 5 mM MgCl2). NaCl concentration was chosen to mimic the 
physiological condition. The incubation was performed for 90 minutes in ice. The sample was then 
loaded in a mini-column (Biorad) filled with Sepharose SP resin (Amersham Pharmacia Biotech) 
previously swollen and equilibrated in buffer IB. The ssDNA/protein solution was incubated with the 
resin for 30 minutes at 4 °C. The unbound oligonucleotides were washed away with buffer IB, while 
the Cathepsin bound sequences were eluted from the column with a high ionic strength buffer (EB 
buffer: 0.8 M NaCl and 50 mM Tris pH 7.8). The eluted fractions were counted and the yield of the 
Selex cycle was expressed as a percentage of the total radioactivity. The flow through and the first EB 
washes, which contain the largest amount of bound ssDNA, were collected, amplified by PCR (90°C 
for 1 min, 50°C for 1 min, 72 °C for 1 min) and rendered single stranded as described above. The Int. J. Mol. Sci. 2008, 9  1019
 
 
number of PCR cycles never exceeded 20. Double stranded DNA after each PCR was gel purified 
through a native 8% PAGE (Tris-borate 89 mM EDTA 2 mM). 
In order to avoid unspecific binding of ssDNA molecules to the SP resin, two precolumn cycles 
were performed after cycle 6 and 8: the ssDNA pool (without CatG) was loaded in a Sepharose SP 
column and washed with buffer IB. The DNA molecules in the first fractions, representing non-matrix 
binders, were collected, precipitated and PCR amplified using Taq polymerase (Amersham) at a 
concentration of 0.3-0.5 U/50 μl in the buffer provided by the supplier, and used in subsequent 
selection cycles. 
 
4.3 Cloning and sequencing 
 
Before the insertion in the plasmid vector for cloning, the DNA was subjected to a polishing 
reaction in order to get blunt ends: an aliquot of the normal PCR reaction, performed with non-
biotinylated Down primer, was incubated with Pfu Turbo polymerase (2.5 U/μL, Stratagene), in the 
suggested buffer at 72°C for 30 minutes. The amplified dsDNA was cleaved with 2.5 units of EcoRI at 
the 5' end. The plasmid vector pUC19 (Amersham) was treated with EcoRI and SmaI that cleaves 
giving blunt ends. After precipitation 3 pmols of dsDNA and 0.6 pmols of pUC19 were reacted with 
T4 ligase in the suggested buffer. The plasmid was then inoculated in E.coli competent cells (SURE 
strain by Stratagene) by the electroporation method using E.coli pulser (Biorad) and plated in solid LB 
media in the presence of Ampicillin (45 μg/mL), X-Gal (40 μg/mL) and IPTG (0.5 mM) for the 
blue/white screening. Fifty white different colonies were picked, grown in liquid LB broth (Becton 
Dickinson) and harvested. The plasmids were purified by alkaline lysis and their quality was tested 
every time by agarose gel electrophoresis. The sequence of the aptamers was determined using T7 
Sequenase (Amersham) and [α-
33P]dATP (Perkin Elmer Life Sciences); the primers EleA457 and 
EleS357 were used for sense and antisense reading respectively. 
 
4.4 Kd determination 
 
The dissociation constant of each oligonucleotide was determined by chromatography in analogy 
with the selection protocol. The labelled oligonucleotides (600 pmoles) were incubated 30’ in ice with 
the protein and then loaded onto a mini-chromatography column filled with Sepharose SP (300 μL, 
Amersham Pharmacia Biotech) and incubated for further 30’. The column was washed with 15 
volumes of buffer IB, then after one further hour of incubation with buffer EB, it was washed with six 
volumes of this buffer. Each volume was collected and counted. Three independent experiments were 
performed for each test sequence using a constant amount of the oligonucleotide and variable amount 
of Cat G (5, 10 and 15 μg). Kds were calculated approximating a first order reaction. 
 
4.5 Surface Plasmon Resonance (SPR) experiments 
 
CatG, from human neutrophils, dissolved in HBS EP buffer, pH 7.40 was immobilized on the 
surface of a CM 5 research grade sensor chip flow cell, according to the procedure suggested by 
Biacore and using the Biacore amine coupling kit (Biacore). A blank flow cell was prepared using all Int. J. Mol. Sci. 2008, 9  1020
 
 
the above reagents but CatG. The amount of CatG immobilized on the surface of the flow cell was 
5178.91 ± 129.63 RU. Tested aptamers were dissolved in Tris-HCl buffer, pH 7.50 (30 mM), NaCl 
(150 mM), KCl (5 mM) and MgCl2 (5 mM) and injected over the CatG surface or the blank surface. 
Experiments at variable (molar or weight) oligonucleotide concentration were performed. All the 
above experiments were run at 25° C, using as running buffer the Biacore HBS EP Buffer, pH 7.4. The 
CatG surface was regenerated by two injections of 2 M NaCl. The blank sensorgram was subtracted 
from each sample sensorgram and the binding response evaluated. The binding responses, generated in 
the third set of experiments, were plotted as a function of the Log concentration (nM) to get 
concentration-effect curves to find out the relative potencies of aptamers in binding CatG.  
 
4.6 Enzymatic assays 
 
The inhibition of the catalytic activity of CatG was evaluated following the extent of hydrolysis of a 
proper chromogenic substrate induced by the proteinase in the presence/absence of test oligonucleotides. 
A solution of 600 nM CatG was incubated for 30 minutes at room temperature with increasing 
concentrations of each oligonucleotide in pH 7.4 phosphate buffer (50 mM), PEG (0.1%). The 
experiments in the presence of albumin were performed using 600 nM of human albumin. The 
substrate Suc-Ala-Ala-Pro-Phe-pNA (Calbiochem) was then added to a final concentration of 350 μM. 
The hydrolysis of p-nitroaniline was followed as a function of time recording the absorbance at 410 nm 
with a Perkin Elmer Lambda 20 spectrophotometer. The initial rate of substrate hydrolysis was 
evaluated from the slope of a plot of absorption at 410 nm vs. time. The ratio of the initial rate in the 
presence/absence of the inhibitor, (vi/v0), has been plotted as a function of DNA concentration, and the 
oligonucleotide concentration which induces a 50% of the maximal reduction of enzyme activity has been 
graphically evaluated. Measurements performed in the presence of increasing concentrations of 
substrate allowed us to evaluate a Km = 7.1 mM well in accordance with literature data [42]. 
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